原发性肝癌肝切除术后肝衰竭的防治进展

麦荣云; 叶甲舟; 白涛; 曾洁; 陈洁; 黄山; 吴飞翔; 黎乐群; 邬国斌

doi:10.3969/j.issn.1001-5256.2018.12.039

原发性肝癌肝切除术后肝衰竭的防治进展

DOI: 10.3969/j.issn.1001-5256.2018.12.039

广西医科大学附属肿瘤医院肝胆外科

基金项目:

国家自然科学基金(81460426)；广西医疗卫生适宜技术开发与推广应用项目(s201629)；

详细信息

中图分类号: R735.7;R575.3
计量
- 文章访问数: 1846
- HTML全文浏览量: 29
- PDF下载量: 341
- 被引次数: 0
出版历程
- 出版日期: 2018-12-20

Advances in the prevention and treatment of posthepatectomy liver failure in patients with primary liver cancer

Research funding:

摘要

摘要: 肝切除术后肝衰竭(PHLF)是导致肝切除术后围手术期死亡的主要原因。总结了目前导致PHLF的因素、预测方法、预防措施及专家共识等方面的研究现况,得出了术前客观评价肝脏的功能状态、合理设计肝脏手术切除方式以及精准操作外科手术是降低PHLF发生率的关键措施。
- 肝肿瘤 /
- 肝切除术 /
- 肝功能衰竭 /
- 肝脏储备功能 /
- 综述
Abstract: Posthepatectomy liver failure (PHLF) is a major cause of perioperative death after hepatectomy. This article summarizes the current status of research on risk factors contributing to PHLF, prediction methods, preventive measures, and related expert consensus, and it is pointed out that an objective evaluation of liver function before surgery, a reasonable design of the method of liver resection, and accurate operation are the key measures to reduce the incidence rate of PHLF.
- liver neoplasms /
- hepatectomy /
- liver failure /
- hepatic reserve function /
- review

HTML全文

参考文献(64)

[1] SIEGEL RL, MILLER KD, JEMAL A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67 (1) :7-30.

[2] RAHBARI NN, GARDEN OJ, PADBURY R, et al. Posthepatectomy liver failure:A definition and grading by the International Study Group of Liver Surgery (ISGLS) [J]. Surgery, 2011, 149 (5) :713-724.

[3] TIMCHENKO NA. Aging and liver regeneration[J]. Trends Endocrinol Metab, 2009, 20 (4) :171-176.

[4] LITTLE SA, JARNAGIN WR, DEMATTEO RP, et al. Diabetes is associated with increased perioperative mortality but equivalent longterm outcome after hepatic resection for colorectal cancer[J]. J Gastrointest Surg, 2002, 6 (1) :88-94.

[5] CUCCHETTI A, CESCON M, ERCOLANI G, et al. Safety of hepatic resection in overweight and obese patients with cirrhosis[J].Br J Surg, 2011, 98 (8) :1147-1154.

[6] El-ZAYADI AR. Heavy smoking and liver[J]. World J Gastroenterol, 2006, 12 (38) :6098-6101.

[7] REHM J, SAMOKHVALOV AV, SHIELD KD. Global burden of alcoholic liver diseases[J]. J Hepatol, 2013, 59 (1) :160-168.

[8] HUO YM, ZHU CC, LU TF, et al. Influence of plasma exchange on transplantation related immune function in patients with liver failure[J]. Genet Mol Res, 2015, 14 (3) :8170-8180.

[9] HUANG G, LAU WY, SHEN F, et al. Preoperative hepatitis B virus DNA level is a risk factor for postoperative liver failure in patients who underwent partial hepatectomy for hepatitis B-related hepatocellular carcinoma[J]. World J Surg, 2014, 38 (9) :2370-2376.

[10] ZHANG B, XU D, WANG R, et al. Perioperative antiviral therapy improves safety in patients with hepatitis B related HCC following hepatectomy[J]. Int J Surg, 2015, 15:1-5.

[11] OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:a 2017 update[J]. Hepatol Int, 2017, 11 (4) :317-370.

[12] WU MC, TANG ZY, YE SL, et al. Expert consensus on antiviral therapy to hepatitis B/C virus-related hepatocellular carcinoma[J]. J Clin Hepatol, 2014, 30 (5) :390-395. (in Chinese) 吴孟超, 汤钊猷, 叶胜龙, 等. HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J].临床肝胆病杂志, 2014, 30 (5) :390-395.

[13] HERNAEZ R, SOLE, MOREAU R, et al. Acute-on-chronic liver failure:An update[J]. Gut, 2017, 66 (3) :541-553.

[14] HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67 (1) :358-380.

[15] LIU YL, ZHANG QZ. An excerpt of the Asia Pacific Working Party on nonalcoholic fatty liver disease guidelines 2017[J]. J Clin Hepatol, 2017, 33 (12) :2278-2282. (in Chinese) 刘应莉, 张秋瓒.《2017年亚太工作组非酒精性脂肪性肝病指南》摘译[J].临床肝胆病杂志, 2017, 33 (12) :2278-2282.

[16] IINABA Y, FURUTANI T, KIMURA K, et al. Growth arrest and DNA damage-inducible 34 regulates liver regeneration in hepatic steatosis in mice[J]. Hepatology, 2015, 61 (4) :1343-1356.

[17] HO MC, HASEGAWA K, CHEN XP, et al. Surgery for intermediate and advanced hepatocellular carcinoma:A consensus report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2014) [J]. Liver Cancer, 2016, 5 (4) :245-256.

[18] WAKABAYASHI G, CHERQUI D, GELLER DA, et al. Recommendations for laparoscopic liver resection:A report from the second international consensus conference held in Morioka[J]. Ann Surg, 2015, 261 (4) :619-629.

[19] SHIBA H, ISHIDA Y, WAKIYAMA S, et al. Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection[J]. J Gastrointest Surg, 2009, 13 (9) :1636-1642.

[20] EMOND JC, RENZ JF, FERRELL LD, et al. Functional analysis of grafts from living donors. Implications for the treatment of older recipients[J]. Ann Surg, 1996, 224 (4) :544-552; discussion552-554.

[21] Study Group of Surgical Operation, Chinese Society of Surgery, Chinese Medical Association; China International Exchange and Promotive Association for Medical and Health Care; Hepatic Surgery Group, Society of Enhanced Recovery after Surgery. Chinese expert consensus on enhanced recovery after hepatectomy (2017) [J]. J Clin Hepatol, 2017, 33 (10) :1876-1882. (in Chinese) 中华医学会外科学分会外科手术学学组, 中国医疗保健国际交流促进会, 加速康复外科学分会肝脏外科学组.肝切除术后加速康复中国专家共识 (2017版) [J].临床肝胆病杂志, 2017, 33 (10) :1876-1882.

[22] DONG JH, ZHENG SS, CHEN XP, et al. Consensus on evaluation of hepatic functional reserve before hepatectomy (2011 edition) [J].Chin J Dig Surg, 2011, 10 (1) :20-25. (in Chinese) 董家鸿, 郑树森, 陈孝平, 等.肝切除术前肝脏储备功能评估的专家共识 (2011版) [J].中华消化外科杂志, 2011, 10 (1) :20-25.

[23] MELLOUL E, HBNER M, SCOTT M, et al. Guidelines for perioperative care for liver surgery:Enhanced Recovery After Surgery (ERAS) society recommendations[J]. World J Surg, 2016, 40 (10) :2425-2440.

[24] WAI CT, GREENSON JK, FONTANA RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology, 2003, 38 (2) :518-526.

[25] MALINCHOC M, KAMATH PS, GORDON FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31 (4) :864-871.

[26] BROWN RS, LAKE JR. The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution[J].Am J Transplant, 2005, 5 (2) :203-204.

[27] CESCON M, CUCCHETTI A, GRAZI GL, et al. Indication of the extent of hepatectomy for hepatocellular carcinoma on cirrhosis by a simple algorithm based on preoperative variables[J]. Arch Surg, 2009, 144 (1) :57-63; discussion 63.

[28] JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al. Assessment of liver function in patients with hepatocellular carcinoma:A new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33 (6) :550-558.

[29] KUO YH, WANG JH, HUNG CH, et al. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use[J]. J Gastroenterol Hepatol, 2017, 32 (12) :1975-1981.

[30] HIRAOKA A, KUMADA T, MICHITAKA K, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2016, 31 (5) :1031-1036.

[31] WANG YY, ZHONG JH, SU ZY, et al. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma[J]. Br J Surg, 2016, 103 (6) :725-734.

[32] LOAEZA-DEL-CASTILLO A, PAZ-PINEDA F, OVIEDOCáRDENAS E, et al. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis[J]. Ann Hepatol, 2008, 7 (4) :350-357.

[33] ICHIKAWA T, UENISHI T, TAKEMURA S, et al. A simple, noninvasively determined index predicting hepatic failure following liver resection for hepatocellular carcinoma[J]. J Hepatobiliary Pancreat Surg, 2009, 16 (1) :42-48.

[34] SHEN SL, FU SJ, CHEN B, et al. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection[J]. Ann Surg Oncol, 2014, 21 (12) :3802-3809.

[35] CHENG J, ZHAO P, LIU J, et al. Preoperative aspartate aminotransferase-to-platelet ratio index (APRI) is a predictor on postoperative outcomes of hepatocellular carcinoma[J]. Medicine (Baltimore) , 2016, 95 (48) :e5486.

[36] MAI RY, YE JZ, WANG YY, et al. Value of albumin-bilirubin score combined with aspartate aminotransferase-to-platelet ratio index in predicting the development of posthepatectomy liver failure in patients with HBV-related hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34 (2) :292-297. (in Chinese) 麦荣云, 叶甲舟, 王言焱, 等. ALBI联合APRI对HBV相关肝细胞癌肝切除术后肝衰竭发生的预测价值[J].临床肝胆病杂志, 2018, 34 (2) :292-297.

[37] GEISEL D, LDEMANN L, HAMM B, et al. Imaging-based liver function tests—past, present and future[J]. Rofo, 2015, 187 (10) :863-871.

[38] PIND ML, BENDTSEN F, KALLEMOSE T, et al. Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis[J]. Eur J Gastroenterol Hepatol, 2016, 28 (8) :948-954.

[39] LEVESQUE E, MARTIN E, DUDAU D, et al. Current use and perspective of indocyanine green clearance in liver diseases[J]. Anaesth Crit Care Pain Med, 2016, 35 (1) :49-57.

[40] National Health and Family Planning Commission of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J]. J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.

[41] KUDO M, MATSUI O, IZUMI N, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma:2014 update by the Liver Cancer Study Group of Japan[J]. Liver Cancer, 2014, 3 (3-4) :458-468.

[42] CHENG XP, ZHAO J, CHEN Y, et al. Comparison of the ability of the PDD-ICG clearance test, CTP, MELD, and MELD-Na to predict short-term and medium-term mortality in patients with decompensated hepatitis B cirrhosis[J]. Eur J Gastroenterol Hepatol, 2016, 28 (4) :444-448.

[43] OGˇUL H, KANTARU M, GENB, et al. Perfusion CT imaging of the liver:Review of clinical applications[J]. Diagn Interv Radiol, 2014, 20 (5) :379-389.

[44] BGIN A, MARTEL G, LAPOINTE R, et al. Accuracy of preoperative automatic measurement of the liver volume by CT-scan combined to a 3D virtual surgical planning software (3DVSP) [J]. Surg Endosc, 2014, 28 (12) :3408-3412.

[45] TONG C, XU X, LIU C, et al. Assessment of liver volume variation to evaluate liver function[J]. Front Med, 2012, 6 (4) :421-427.

[46] SIRIWARDANA RC, CHAN SC, CHOK KS, et al. Effects of the liver volume and donor steatosis on errors in the estimated standard liver volume[J]. Liver Transpl, 2011, 17 (12) :1437-1442.

[47] TAMADA T, ITO K, HIGAKI A, et al. Gd-EOB-DTPA-enhanced MR imaging:Evaluation of hepatic enhancement effects in normal and cirrhotic livers[J]. Eur J Radiol, 2011, 80 (3) :e311-e316.

[48] QIAO YG, AO GK, DONG X, et al. 3. 0 T magnetic resonance Gd-EOB-DTPA MRC application value in bile duct diseases[J].Clin J Med Offic, 2017, 45 (8) :835-839. (in Chinese) 乔远罡, 敖国昆, 董莘, 等. 3. 0T磁共振钆塞酸二钠磁共振胆管造影术在胆管疾病中应用[J].临床军医杂志, 2017, 45 (8) :835-839.

[49] OKABAYASHIk T, SHIMA Y, MORITA S, et al. Liver function assessment using technetium 99m-galactosyl single-photon emission computed tomography/CT fusion imaging:A prospective trial[J]. J Am Coll Surg, 2017, 225 (6) :789-797.

[50] KIM YK, NAKANO H, YAMAGUCHI M, et al. Prediction of postoperative decompensated liver function by technetium-99m galactosyl-human serum albumin liver scintigraphy in patients with hepatocellular carcinoma complicating chronic liver disease[J]. Br J Surg, 1997, 84 (6) :793-796.

[51] SUMIYOSHI T, SHIMA Y, OKABAYASHIk T, et al. Liver function assessment using 99mTc-GSA single-photon emission computed tomography (SPECT) /CT fusion imaging in hilar bile duct cancer:A retrospective study[J]. Surgery, 2016, 160 (1) :118-126.

[52] EASL clinical practice guidelines:Management of hepatitis C virus infection[J]. J Hepatol, 2014, 60 (2) :392-420.

[53] POON RT, CHEUNG TT, KWOK PC, et al. Hong Kong consensus recommendations on the management of hepatocellular carcinoma[J]. Liver Cancer, 2015, 4 (1) :51-69.

[54] WATANABE M, SHIBUYAh A, TAKADA J, et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation:A review of 16 patients[J]. Eur J Intern Med, 2010, 21 (4) :333-337.

[55] Chinese Research Hospital Association, Society for Hepatopancreatobiliary Surgery. Expert consensus on presicion liver resection[J]. Chin J Dig Surg, 2017, 16 (9) :883-893. (in Chinese) 中国研究型医院学会肝胆胰外科专业委员会.精准肝切除术专家共识[J].中华消化外科杂志, 2017, 16 (9) :883-893.

[56] FANG CH, TAO HS, YANG J, et al. Impact of three-dimensional reconstruction technique in the operation planning of centrally located hepatocellular carcinoma[J]. J Am Coll Surg, 2015, 220 (1) :28-37.

[57] DIMITROULIS D, TSAPARAS P, VALSAMI S, et al. Indications, limitations and maneuvers to enable extended hepatectomy:Current trends[J]. World J Gastroenterol, 2014, 20 (24) :7887-7893.

[58] TRESKA V. Methods to increase future liver remnant volume in patients with primarily unresectable colorectal liver metastases:Current state and future perspectives[J]. Anticancer Res, 2016, 36 (5) :2065-2071.

[59] MANSOUR JC, ALOIA TA, CRANE CH, et al. Hilar cholangiocarcinoma:Expert consensus statement[J]. HPB (Oxford) , 2015, 17 (8) :691-699.

[60] OGATA S, BELGHITI J, FARGES O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma[J]. Br J Surg, 2006, 93 (9) :1091-1098.

[61] D'HAESE JG, NEUMANN J, WENIGER M, et al. Should ALPPS be used for liver resection in intermediate-stage HCC?[J]. Ann Surg Oncol, 2016, 23 (4) :1335-1343.

[62] SCHNITZBAUER AA, LANG SA, GOESSMANN H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings[J]. Ann Surg, 2012, 255 (3) :405-414.

[63] Chinese Chapter of International Hepato-Pancreato-Biliary Association, Hepatic Surgery Group, Chinese Society of Surgery, Chinese Medical Association. Diagnosis and treatment of cholangiocarcinoma:Surgical expert consensus[J]. J Clin Hepatol, 2015, 31 (1) :12-16. (in Chinese) 国际肝胆胰学会中国分会, 中华医学会外科学分会肝脏外科学组.胆管癌诊断与治疗—外科专家共识[J].临床肝胆病杂志, 2015, 31 (1) :12-16.

[64] MIYAZAKI M, YOSHITOMI H, MIYAKAWA S, et al. Clinical practice guidelines for the management of biliary tract cancers 2015:The 2nd English edition[J]. J Hepatobiliary Pancreat Sci, 2015, 22 (4) :249-273.

施引文献

资源附件(0)

访问统计